New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
10:30 EDTPSDV, INO, NI, DKSHigh option volume stocks: INO NI DKS KOL PSDV
News For PSDV;INO;NI;DKS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
06:38 EDTNINiSource reports Q3 EPS 14c, consensus 16c
Subscribe for More Information
October 29, 2014
15:41 EDTNINotable companies reporting before tomorrow's open
Subscribe for More Information
October 27, 2014
07:33 EDTPSDVpSivida receives $25M milestone payment
pSivida announced that it has received the $25M milestone payment under its out-license of ILUVIEN for the treatment of diabetic macular edema. The milestone was earned on the approval of ILUVIEN by the U.S. Food and Drug Administration. This milestone payment together with our cash on hand should fund our planned product development and other operations into calendar 2017. In addition, we will receive 20% of any net profits from sales of ILUVIEN for DME on a country-by-country basis as well as royalties on sales of Retisert, said Dr. Paul Ashton, Ph.D., President and CEO of pSivida Corp.
October 23, 2014
13:02 EDTDKSCabela's tumbles after results, guidance miss expectations
Subscribe for More Information
October 21, 2014
06:10 EDTINOInovio, MedImmune, UPENN awarded $12.2M collaborative study by DARPA
Inovio Pharmaceuticals (INO) announced the Defense Advanced Research Projects Agency, or DARPA, has awarded $12.2M for a collaborative study that will be conducted by scientists from the Perelman School of Medicine at the University of Pennsylvania; Inovio Pharmaceuticals; and MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The group will develop DNA-based monoclonal antibodies, or mAbs, for infectious disease treatment. DARPA is an agency of the US Department of Defense that creates and supports novel technologies important for national security. Together, the three organizations will develop and assess the DNA mAbs in preclinical studies using technology developed by Penn and licensed by Inovio. The collaboration will focus on three disease areas influenza virus, Pseudomonas aeruginosa and Staphylococcus aureus.
October 20, 2014
06:47 EDTDKSDick's Sporting shares have value at current levels, says Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use